PER Spectives

This podcast features engaging commentary from experts in the clinical management of patients with sickle cell disease:  Nirmish Shad, MD from Duke University Medical Center, Matthew Heeney, MD Matthew Heeney, MD from Harvard Medical School, and Charles R. Jonassaint, PhD, MHS from University of Pittsburgh School of Medicine. These experts review clinical guidelines, interpret clinical data regard...

Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or u...

Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or u...

Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or u...

Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or u...

Our ever-advancing understanding of oncogenic drivers in non–small cell lung cancer (NSCLC) has led to an expanding armamentarium of targeted therapy options. Given the availability of recently emerging, highly efficacious treatments, it is more important than ever that patients with NSCLC undergo comprehensive testing to identify targetable alterations. Many therapies are currently available or u...

During this educational Tumor Board, breast cancer specialists will showcase challenging scenarios in metastatic and non-metastatic HR+ disease and contextualize data from pivotal clinical trials to optimize decision-making for patients with HR+/HER2- breast cancer. Featuring:  Fátima Cardoso, MD Director, Breast Unit Champalimaud Clinical Center Lisbon, Portugal Mario Campone, MD, PhD Chief Execu...

Dr. Eden Miller and Kim Zuber, PA-C, discuss the importance of screening patients with chronic kidney disease (CKD) for comorbidities and treating them early. They also discuss the treatment options available among both current and emerging classes of therapies and across different clinical subspecialties. After you listen to this podcast, go to https://www.gotoper.com/2022consckd to learn more an...

Tumor-infiltrating lymphocyte (TIL) is an emerging therapy that may one day change the approach to the management of solid tumors including melanoma, NSCLC, and more. Join us for a conversation with Dr. Omid Hamid, one of the principal investigators pioneering TIL therapy in clinical trials, as we discuss this novel treatment method. Dr. Hamid will break down what the community physician needs to...